Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-05, Vol.30 (5), p.663-665 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 665 |
|---|---|
| container_issue | 5 |
| container_start_page | 663 |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | van Waalwijk van Doorn-Khosrovani, S.B. Pisters-van Roy, A. van Saase, L. van der Graaff, M. Gijzen, J. Sleijfer, S. Hoes, L.R. van Berge Henegouwen, J.M. van der Wijngaart, H. van der Velden, D.L. van Werkhoven, E. Retel, V.P. van Harten, W.H. Huitema, A.D.R. Timmers, L. Gelderblom, H. Verheul, H.M.W. Voest, E.E. |
| description | |
| doi_str_mv | 10.1093/annonc/mdz119 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2217477393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdz119</oup_id><els_id>S0923753419311779</els_id><sourcerecordid>2217477393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-ae689431546ea949a0c27923a480d23cd3ff1a250c71aa85737eedaeeae0ff3a3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EokvhyBX5yCXUjpN1zA1V5UOqBAc4W7P2pJgm9jKTVIJfj1cpcEKcRho9887MI8RzrV5p5cwF5FxyuJjjT63dA7HT_d41g-r0Q7FTrjWN7U13Jp4wf1NK7V3rHoszo5UZdN_txPIJiUuGKTFGSZjmw0qMM-bltQRJiW8b_gqU8o2cS8RJjoXkIZUZ6BapiZTuMMuFEJbTkCyjJCCUvB5uqKxHPnUC5IAkj7CkyvBT8WiEifHZfT0XX95efb5831x_fPfh8s11EzptlgZwP7jO1Dv3CK5zoEJr60vQDSq2JkQzjhraXgWrAYbeGosYARFQjaMBcy5ebrlHKt9X5MXPiQNOE2QsK_u21baz1jhT0WZDAxVmwtEfKdUff3it_Em030T7TXTlX9xHr4cZ4x_6t9m_u6uD_2bZDcXq4i4heQ7VU8CYCMPiY0n_mPwFBxKgHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2217477393</pqid></control><display><type>article</type><title>Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>van Waalwijk van Doorn-Khosrovani, S.B. ; Pisters-van Roy, A. ; van Saase, L. ; van der Graaff, M. ; Gijzen, J. ; Sleijfer, S. ; Hoes, L.R. ; van Berge Henegouwen, J.M. ; van der Wijngaart, H. ; van der Velden, D.L. ; van Werkhoven, E. ; Retel, V.P. ; van Harten, W.H. ; Huitema, A.D.R. ; Timmers, L. ; Gelderblom, H. ; Verheul, H.M.W. ; Voest, E.E.</creator><creatorcontrib>van Waalwijk van Doorn-Khosrovani, S.B. ; Pisters-van Roy, A. ; van Saase, L. ; van der Graaff, M. ; Gijzen, J. ; Sleijfer, S. ; Hoes, L.R. ; van Berge Henegouwen, J.M. ; van der Wijngaart, H. ; van der Velden, D.L. ; van Werkhoven, E. ; Retel, V.P. ; van Harten, W.H. ; Huitema, A.D.R. ; Timmers, L. ; Gelderblom, H. ; Verheul, H.M.W. ; Voest, E.E.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdz119</identifier><identifier>PMID: 31038154</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Cost-Benefit Analysis ; Health Services Accessibility - economics ; Humans ; Molecular Diagnostic Techniques - economics ; Molecular Targeted Therapy - economics ; Neoplasms - classification ; Neoplasms - drug therapy ; Neoplasms - economics ; Neoplasms - genetics ; Netherlands ; Precision Medicine - economics ; Reimbursement Mechanisms - economics ; Survival Rate</subject><ispartof>Annals of oncology, 2019-05, Vol.30 (5), p.663-665</ispartof><rights>2019 THE AUTHORS</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-ae689431546ea949a0c27923a480d23cd3ff1a250c71aa85737eedaeeae0ff3a3</citedby><cites>FETCH-LOGICAL-c413t-ae689431546ea949a0c27923a480d23cd3ff1a250c71aa85737eedaeeae0ff3a3</cites><orcidid>0000-0002-4112-9105</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31038154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Waalwijk van Doorn-Khosrovani, S.B.</creatorcontrib><creatorcontrib>Pisters-van Roy, A.</creatorcontrib><creatorcontrib>van Saase, L.</creatorcontrib><creatorcontrib>van der Graaff, M.</creatorcontrib><creatorcontrib>Gijzen, J.</creatorcontrib><creatorcontrib>Sleijfer, S.</creatorcontrib><creatorcontrib>Hoes, L.R.</creatorcontrib><creatorcontrib>van Berge Henegouwen, J.M.</creatorcontrib><creatorcontrib>van der Wijngaart, H.</creatorcontrib><creatorcontrib>van der Velden, D.L.</creatorcontrib><creatorcontrib>van Werkhoven, E.</creatorcontrib><creatorcontrib>Retel, V.P.</creatorcontrib><creatorcontrib>van Harten, W.H.</creatorcontrib><creatorcontrib>Huitema, A.D.R.</creatorcontrib><creatorcontrib>Timmers, L.</creatorcontrib><creatorcontrib>Gelderblom, H.</creatorcontrib><creatorcontrib>Verheul, H.M.W.</creatorcontrib><creatorcontrib>Voest, E.E.</creatorcontrib><title>Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cost-Benefit Analysis</subject><subject>Health Services Accessibility - economics</subject><subject>Humans</subject><subject>Molecular Diagnostic Techniques - economics</subject><subject>Molecular Targeted Therapy - economics</subject><subject>Neoplasms - classification</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - economics</subject><subject>Neoplasms - genetics</subject><subject>Netherlands</subject><subject>Precision Medicine - economics</subject><subject>Reimbursement Mechanisms - economics</subject><subject>Survival Rate</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EokvhyBX5yCXUjpN1zA1V5UOqBAc4W7P2pJgm9jKTVIJfj1cpcEKcRho9887MI8RzrV5p5cwF5FxyuJjjT63dA7HT_d41g-r0Q7FTrjWN7U13Jp4wf1NK7V3rHoszo5UZdN_txPIJiUuGKTFGSZjmw0qMM-bltQRJiW8b_gqU8o2cS8RJjoXkIZUZ6BapiZTuMMuFEJbTkCyjJCCUvB5uqKxHPnUC5IAkj7CkyvBT8WiEifHZfT0XX95efb5831x_fPfh8s11EzptlgZwP7jO1Dv3CK5zoEJr60vQDSq2JkQzjhraXgWrAYbeGosYARFQjaMBcy5ebrlHKt9X5MXPiQNOE2QsK_u21baz1jhT0WZDAxVmwtEfKdUff3it_Em030T7TXTlX9xHr4cZ4x_6t9m_u6uD_2bZDcXq4i4heQ7VU8CYCMPiY0n_mPwFBxKgHA</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>van Waalwijk van Doorn-Khosrovani, S.B.</creator><creator>Pisters-van Roy, A.</creator><creator>van Saase, L.</creator><creator>van der Graaff, M.</creator><creator>Gijzen, J.</creator><creator>Sleijfer, S.</creator><creator>Hoes, L.R.</creator><creator>van Berge Henegouwen, J.M.</creator><creator>van der Wijngaart, H.</creator><creator>van der Velden, D.L.</creator><creator>van Werkhoven, E.</creator><creator>Retel, V.P.</creator><creator>van Harten, W.H.</creator><creator>Huitema, A.D.R.</creator><creator>Timmers, L.</creator><creator>Gelderblom, H.</creator><creator>Verheul, H.M.W.</creator><creator>Voest, E.E.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4112-9105</orcidid></search><sort><creationdate>201905</creationdate><title>Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients</title><author>van Waalwijk van Doorn-Khosrovani, S.B. ; Pisters-van Roy, A. ; van Saase, L. ; van der Graaff, M. ; Gijzen, J. ; Sleijfer, S. ; Hoes, L.R. ; van Berge Henegouwen, J.M. ; van der Wijngaart, H. ; van der Velden, D.L. ; van Werkhoven, E. ; Retel, V.P. ; van Harten, W.H. ; Huitema, A.D.R. ; Timmers, L. ; Gelderblom, H. ; Verheul, H.M.W. ; Voest, E.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-ae689431546ea949a0c27923a480d23cd3ff1a250c71aa85737eedaeeae0ff3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cost-Benefit Analysis</topic><topic>Health Services Accessibility - economics</topic><topic>Humans</topic><topic>Molecular Diagnostic Techniques - economics</topic><topic>Molecular Targeted Therapy - economics</topic><topic>Neoplasms - classification</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - economics</topic><topic>Neoplasms - genetics</topic><topic>Netherlands</topic><topic>Precision Medicine - economics</topic><topic>Reimbursement Mechanisms - economics</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Waalwijk van Doorn-Khosrovani, S.B.</creatorcontrib><creatorcontrib>Pisters-van Roy, A.</creatorcontrib><creatorcontrib>van Saase, L.</creatorcontrib><creatorcontrib>van der Graaff, M.</creatorcontrib><creatorcontrib>Gijzen, J.</creatorcontrib><creatorcontrib>Sleijfer, S.</creatorcontrib><creatorcontrib>Hoes, L.R.</creatorcontrib><creatorcontrib>van Berge Henegouwen, J.M.</creatorcontrib><creatorcontrib>van der Wijngaart, H.</creatorcontrib><creatorcontrib>van der Velden, D.L.</creatorcontrib><creatorcontrib>van Werkhoven, E.</creatorcontrib><creatorcontrib>Retel, V.P.</creatorcontrib><creatorcontrib>van Harten, W.H.</creatorcontrib><creatorcontrib>Huitema, A.D.R.</creatorcontrib><creatorcontrib>Timmers, L.</creatorcontrib><creatorcontrib>Gelderblom, H.</creatorcontrib><creatorcontrib>Verheul, H.M.W.</creatorcontrib><creatorcontrib>Voest, E.E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Waalwijk van Doorn-Khosrovani, S.B.</au><au>Pisters-van Roy, A.</au><au>van Saase, L.</au><au>van der Graaff, M.</au><au>Gijzen, J.</au><au>Sleijfer, S.</au><au>Hoes, L.R.</au><au>van Berge Henegouwen, J.M.</au><au>van der Wijngaart, H.</au><au>van der Velden, D.L.</au><au>van Werkhoven, E.</au><au>Retel, V.P.</au><au>van Harten, W.H.</au><au>Huitema, A.D.R.</au><au>Timmers, L.</au><au>Gelderblom, H.</au><au>Verheul, H.M.W.</au><au>Voest, E.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2019-05</date><risdate>2019</risdate><volume>30</volume><issue>5</issue><spage>663</spage><epage>665</epage><pages>663-665</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31038154</pmid><doi>10.1093/annonc/mdz119</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-4112-9105</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-05, Vol.30 (5), p.663-665 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2217477393 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Cost-Benefit Analysis Health Services Accessibility - economics Humans Molecular Diagnostic Techniques - economics Molecular Targeted Therapy - economics Neoplasms - classification Neoplasms - drug therapy Neoplasms - economics Neoplasms - genetics Netherlands Precision Medicine - economics Reimbursement Mechanisms - economics Survival Rate |
| title | Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T10%3A31%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Personalised%20reimbursement:%20a%20risk-sharing%20model%20for%20biomarker-driven%20treatment%20of%20rare%20subgroups%20of%20cancer%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=van%20Waalwijk%20van%20Doorn-Khosrovani,%20S.B.&rft.date=2019-05&rft.volume=30&rft.issue=5&rft.spage=663&rft.epage=665&rft.pages=663-665&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdz119&rft_dat=%3Cproquest_cross%3E2217477393%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2217477393&rft_id=info:pmid/31038154&rft_oup_id=10.1093/annonc/mdz119&rft_els_id=S0923753419311779&rfr_iscdi=true |